Sana Biotechnology (NASDAQ:SANA) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Sana Biotechnology (NASDAQ:SANA) issued its earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04), Zacks reports.

Sana Biotechnology Stock Up 5.4 %

Shares of SANA traded up $0.25 during mid-day trading on Friday, reaching $4.91. The company had a trading volume of 2,261,241 shares, compared to its average volume of 1,825,041. The stock has a market capitalization of $1.09 billion, a P/E ratio of -3.21 and a beta of 1.45. Sana Biotechnology has a 52-week low of $2.74 and a 52-week high of $12.00. The stock has a 50 day moving average of $5.90 and a two-hundred day moving average of $7.53.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright cut their price objective on Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday. Citigroup increased their price target on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Friday. Finally, Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research note on Wednesday, June 26th. They set a “buy” rating and a $16.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $14.25.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.